June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Efficacy and Safety of Voriconazole and Amphotericin B as Additives in Optisol-GS Corneal Storage Media Against Candida Species
Author Affiliations & Notes
  • Noelle Layer
    Ophthalmology, University of California, San Francisco, San Francisco, CA
  • Vicky Cevallos
    Francis I. Proctor Foundation, San Francisco, CA
  • Andrew Maxwell
    SightLife, Seattle, WA
  • Caroline Ulrickson
    SightLife, Seattle, WA
  • Jeremy Keenan
    Ophthalmology, University of California, San Francisco, San Francisco, CA
    Francis I. Proctor Foundation, San Francisco, CA
  • Bennie Jeng
    Ophthalmology, University of California, San Francisco, San Francisco, CA
    Francis I. Proctor Foundation, San Francisco, CA
  • Footnotes
    Commercial Relationships Noelle Layer, None; Vicky Cevallos, None; Andrew Maxwell, None; Caroline Ulrickson, None; Jeremy Keenan, None; Bennie Jeng, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2897. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Noelle Layer, Vicky Cevallos, Andrew Maxwell, Caroline Ulrickson, Jeremy Keenan, Bennie Jeng; Efficacy and Safety of Voriconazole and Amphotericin B as Additives in Optisol-GS Corneal Storage Media Against Candida Species. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2897.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Optisol-GS is the most commonly used corneal storage medium in the United States; however, it currently does not include an antifungal additive. The purpose of this study was to assess the efficacy and safety of voriconazole and amphotericin B in reducing Candida contamination of Optisol-GS under normal storage conditions.

Methods: Vials of Optisol-GS were supplemented with either voriconazole at 1x, 10x, 25x, or 50x minimum inhibitory concentration (MIC) or amphotericin B at 0.25x, 0.5x, 1x, or 10x MIC. Unsupplemented control groups were also used. Isolates of C. albicans and C. glabrata were each added to a set of vials, which were refrigerated at 4 degrees C. On days 2, 7, and 14, samples were taken to determine viable colony counts immediately after removal from refrigeration and after warming to room temperature for 2 hours. Safety studies were performed by separating 15 pairs of donor corneas into unsupplemented Optisol-GS or Optisol-GS plus voriconazole at 50x MIC, or Optisol-GS plus amphotericin B at 0.25x, 0.5x, 1x, or 10x MIC. Corneal thickness via pachymetry and endothelial cell density (ECD) via specular microscopy were determined at days 0 and 7.

Results: Growth of C. albicans and C. glabrata in Optisol-GS was observed at each concentration of voriconazole. In contrast, with supplementation of amphotericin B, there was no growth of C. albicans by day 2 or C. glabrata by day 7 at all concentrations. Viable counts of C. glabrata were reduced by 99% and 96% with amphotericin B supplementation at 0.25x and 0.5x MIC, respectively, on day 2. Compared to paired controls, there was a significant reduction in ECD with Optisol-GS plus amphotericin B at 10x MIC (P = 0.04), a similar trend with amphotericin B at 1x (P = 0.07), and no significant difference at other concentrations.

Conclusions: The addition of amphotericin B, but not voriconazole, to Optisol-GS may significantly improve activity against contamination with Candida spp., a major cause of fungal endophthalmitis after corneal transplantation. While there appears to be toxicity to the corneal endothelium at the maximal concentration of amphotericin B studied, there is no evidence for toxicity at the lower doses. A larger study is warranted to confirm these findings.

Keywords: 483 cornea: storage • 422 antibiotics/antifungals/antiparasitics • 530 fungal disease  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×